663620-73-3

Basic information

• Product Name: 4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl-2-(4-morpholinyl)-9-[1-[[2-(1H-tetrazol-5-yl)phenyl]amino]ethyl]-
• CAS NO: 663620-73-3
• Molecular Formula: C22H24N8O2
• Mol File: 663620-73-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl-2-(4-morpholinyl)-9-[1-[[2-(1H-tetrazol-5-yl)phenyl]amino]ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl-2-(4-morpholinyl)-9-[1-[[2-(1H-tetrazol-5-yl)phenyl]amino]ethyl]-(663620-73-3)
• EPA Substance Registry System: 4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl-2-(4-morpholinyl)-9-[1-[[2-(1H-tetrazol-5-yl)phenyl]amino]ethyl]-(663620-73-3)

Safety Data

• Hazardous Substances Data: 663620-73-3(Hazardous Substances Data)

Upstream product

• 18216-38-1 5-(2-aminophenyl)tetrazole 
• 1173900-35-0 9-(1-hydroxyethyl)-7-methyl-2-morpholino-4H-pyrido[1,2-a]pyrimidin-4-one 

Relevant articles and documents

Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine- 7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents

Optimization of AZD6482 (2), the first antiplatelet PI3Kβ inhibitor evaluated in man, focused on improving the pharmacokinetic profile to a level compatible with once daily oral dosing as well as achieving adequate selectivity towards PI3Kα to minimize the risk for insulin resistance. Structure-based design and optimization of DMPK properties resulted in (R)-16, a novel, orally bioavailable PI3Kβ inhibitor with potent in vivo anti-thrombotic effect with excellent separation to bleeding risk and insulin resistance.